

1 **SARS-CoV-2 antibody prevalence among industrial livestock operation workers and**
2 **nearby community residents, North Carolina, USA, 2021-2022**

3 Carolyn Gigot^{a#}, Nora Pisanic^a, Kate Kruczynski^a, Magdielis Gregory Rivera^a, Kristoffer Spicer^a,
4 Kathleen M. Kurowski^a, Pranay Randad^a, Kirsten Koehler^a, William A. Clarke^b, Phyla Holmes^c,
5 DJ Hall, Jr.^c, Devon Hall, Sr.^c, Christopher D. Heaney^{a,d,e#}

6
7 ^aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of
8 Public Health, Baltimore, Maryland, USA

9 ^bDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland,
10 USA

11 ^cRural Empowerment Association for Community Help, Warsaw, North Carolina, USA

12 ^dDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
13 Maryland, USA

14 ^eDepartment of International Health, Johns Hopkins Bloomberg School of Public Health,
15 Baltimore, Maryland, USA

16

17 Running Head: SARS-CoV-2 IgG: livestock workers and nearby residents

18

19 #Address correspondence to Carolyn Gigot, cgigot1@jhu.edu and Christopher D. Heaney,
20 cheaney1@jhu.edu

21

22 *Present address: Magdielis Gregory Rivera, Amentum, Falls Church, Virginia, USA.

23 *Present address: Pranay Randad, Flagship Pioneering, Cambridge, Massachusetts, USA.

24 Abstract word count: 347

25 Main text word count: 3663 (without Materials and Methods, References, tables, or figure
26 legends)

27 **ABSTRACT**

28 Industrial livestock operations (ILOs), particularly processing facilities, emerged as
29 centers of coronavirus disease 2019 (COVID-19) outbreaks in spring 2020. Confirmed cases of
30 COVID-19 underestimate true prevalence. To investigate prevalence of antibodies against
31 SARS-CoV-2, we enrolled 279 participants in North Carolina from February 2021 to July 2022:
32 90 from households with at least one ILO worker (ILO), 97 from high-ILO intensity areas (ILO
33 neighbors – ILON), and 92 from metropolitan areas (Metro). Participants provided a saliva swab
34 we analyzed for SARS-CoV-2 IgG using a multiplex immunoassay. Prevalence of infection-
35 induced IgG (positive for nucleocapsid and receptor binding domain) was higher among ILO
36 (63%) compared to ILON (42.9%) and Metro (48.7%) participants (prevalence ratio [PR] =1.38;
37 95% confidence interval [CI]: 1.06, 1.80; ref. ILON and Metro combined). Prevalence of
38 infection-induced IgG was also higher among ILO participants compared to an Atlanta
39 healthcare worker cohort (PR=2.45, 95% CI: 1.8, 3.3) and a general population cohort in North
40 Carolina (PRs 6.37-10.67). Infection-induced IgG prevalence increased over the study period.
41 Participants reporting not masking in public in the past two weeks had higher infection-induced
42 IgG prevalence (78.6%) compared to participants reporting masking (49.3%) (PR=1.59; 95% CI:
43 1.19, 2.13). Lower education, more people per bedroom, Hispanic/Latino ethnicity, and more
44 contact with people outside the home were also associated with higher infection-induced IgG
45 prevalence. Similar proportions of ILO (51.6%), ILON (48.4%), and Metro (55.4%) participants
46 completed the COVID-19 primary vaccination series; median completion was more than four
47 months later for ILO compared to ILON and Metro participants.

48

49 *Importance*

50 Few studies have measured COVID-19 seroprevalence in North Carolina, especially
51 among rural, Black, and Hispanic/Latino communities that have been heavily affected. Antibody
52 results show high rates of COVID-19 among industrial livestock operation workers and their

53 household members. Antibody results add to evidence of health disparities in COVID-19 by
54 socioeconomic status and ethnicity. Associations between masking and physical distancing with
55 antibody results also add to evidence of the effectiveness of these prevention strategies. Delays
56 in the timing of receipt of COVID-19 vaccination reinforce the importance of dismantling
57 vaccination barriers, especially for industrial livestock operation workers and their household
58 members.

59

60 **KEYWORDS**

61 COVID-19, SARS-CoV-2; seroprevalence; industrial livestock operations; health disparities

62

63 **ACKNOWLEDGEMENTS**

64 This study was supported by an anonymous gift, the JHU COVID-19 Research and
65 Response Program, the FIA Foundation, and NIAID R21 R21AI139784. C.G., K.M.K., K.
66 Koehler, and C.D.H. were supported by NIOSH ERC T42 OH0008428. Additionally, N.P., K.
67 Kruczynski, M.G.R., K.S., and C.D.H. were supported by an anonymous gift, the JHU COVID-19
68 Research and Response Program, and the FIA Foundation. The C3PI Study was funded by
69 research grants to Duke University from the NCDHHS and the Center for Disease Control and
70 Prevention (CDC). The MURDOCK Study was funded by a gift from the David H. Murdock
71 Institute for Business and Culture and is supported by Duke's NIH National Center for
72 Advancing Translational Sciences (NCATS) Clinical and Translational Science Award (CTSA)
73 UL1TR002553. Additional support was provided by the Duke Claude D. Pepper Older
74 Americans Independence Center Grant, 5P30AG028716-15.

75 We thank the community organizers at the Rural Empowerment Association for
76 Community Help (REACH), especially Margaret Carr, Clesha Hall, Unique Hall, Angela
77 Matthews, Arika Miller, and Helen Santizo, as well as all participants, without whom this study
78 would not have been possible. We acknowledge Caryn Kok and Eric Xu for assistance with

79 antibody testing. We also acknowledge Dr. Matthew H. Collins for sharing antibody prevalence
80 data from the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study and Douglas
81 Wixted and Dr. L. Kristin Newby for sharing antibody prevalence data from the C3PI Study.

82

83 **INTRODUCTION**

84 North Carolina is the second largest hog, third largest turkey, and fourth largest broiler
85 chicken producing state (1). Animal slaughtering and processing workers have more than twice
86 the rate of injury and illness (6.7 per 100 full-time equivalents) and animal production workers
87 close to twice the rate of injury and illness (5.2 per 100 full-time equivalents) compared to all US
88 workers (2.9 per 100 full-time equivalents), despite reporting exemptions and other factors likely
89 resulting in injury and illness undercounts (2–5). Hog and poultry production have also been
90 associated with a range of adverse health outcomes among nearby community residents,
91 including respiratory health problems and infectious diseases (6–8). Since winter 2019, COVID-
92 19 has become a health hazard associated with working at or living near industrial livestock
93 operations (ILOs). Tens of thousands of cases of COVID-19 have been associated with working
94 at meat and poultry processing facilities (9–11). Taylor et al. found an association between
95 county livestock processing plants and county COVID-19 incidence, estimating as many as 8%
96 of US cases through summer 2020 could be linked to processing plants (12). High numbers of
97 COVID-19 cases have also been associated with food processing, food manufacturing, and
98 agricultural workplaces more broadly (13). COVID-19 has disproportionately burdened low
99 income communities of color (14–16). Disparities by race and ethnicity are also evident among
100 livestock processing and agricultural workers (10, 13).

101 Given limited access to SARS-CoV-2 molecular testing, particularly for asymptomatic or
102 mild COVID-19 cases, and limitations in molecular test reporting, SARS-CoV-2 antibody testing
103 represents an attractive strategy to estimate COVID-19 prevalence, attack rates, and population
104 immunity due to prior infection and/or vaccination (17, 18). SARS-CoV-2 antibodies in oral fluid

105 (hereafter, salivary) have been shown to correspond to SARS-CoV-2 antibodies present in
106 blood and to differentiate between PCR-confirmed cases and pre-COVID-19 samples with high
107 sensitivity and specificity (19–21). Compared to blood collection, saliva collection is painless,
108 safe, and readily self-collected at home and mailed to a testing lab. However, saliva has been
109 less frequently used for surveillance (20, 22).

110 We used a salivary multiplex immunoassay targeting IgG responses to SARS-CoV-2
111 nucleocapsid (N), receptor-binding domain (RBD), and spike (S) protein to differentiate between
112 infection-induced versus infection- and/or vaccination-induced immune response. Infection
113 induces antibodies against all proteins, while the mRNA (Pfizer-BioNTech, Moderna), Janssen
114 (Johnson & Johnson), and Novavax vaccines currently approved for use in the United States
115 induce RBD- and S-specific antibodies only (23). Accordingly, individuals testing positive for
116 both SARS-CoV-2 N and RBD IgG likely experienced infection (24).

117 In this study, we measured salivary SARS-CoV-2 IgG prevalence in a cohort of North
118 Carolina households enrolled in collaboration with REACH (Rural Empowerment Association for
119 Community Help), a community group based in Duplin County, North Carolina. We aimed to (a)
120 compare infection-induced IgG prevalence between participants living in households with at
121 least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal
122 rendering plant (industrial livestock operation household group – ILO), participants living nearby
123 these facilities without any known occupational exposure to livestock (ILO neighbors – ILON),
124 and participants living in metropolitan areas of North Carolina (Metro); (b) identify risk factors for
125 infection-induced IgG prevalence within our study population; and (c) compare infection-induced
126 IgG prevalence between ILO participants and a cohort of other high-risk occupation workers
127 sampled using the same assay, as well as a general population-representative cohort in North
128 Carolina.

129

130 **RESULTS**

131 *Participant characteristics*

132 A total of 279 individuals from 240 households (80 ILO, 80 ILON, and 80 Metro)
133 participated (Table 1). ILON participants were generally enrolled earliest, with a median
134 interview date of June 6, 2021, followed by Metro participants (median August 18, 2021), and
135 ILO participants (median February 9, 2022). Overall, ILON participants were older than ILO and
136 Metro participants. Roughly half of ILO and ILON participants were female, compared to 72.8%
137 of Metro participants. Most participants in all groups were Black; more Metro participants were
138 White and fewer were Hispanic/Latino compared to ILO and ILON participants. Education level
139 differed between groups: most ILO participants had a high school education or lower, while
140 most Metro participants had post-high school education. Most participants lived in homes with
141 one or fewer household members per bedroom, although ILO participants reported more
142 household members per bedroom compared to ILON and Metro participants. The majority of
143 participants reported that their household's primary health care provider was a private doctor or
144 clinic. However, more ILON (15.5%) compared to ILO (13.3%) and Metro (8.7%) participants
145 reported not having health insurance. More than twice as many ILO participants (91.1%)
146 reported working in person compared to ILON (42.3%) and Metro (40.2%) participants.

147

148 **Table 1.** *Participant characteristics by study group*

Characteristic	ILO n=90		ILON n=97		Metro n=92	
	(80 households)		(80 households)		(80 households)	
Sampling date, median (range)	2/9/2022	(4/2/2021- 7/18/2022)	6/6/2021	(3/8/2021- 6/3/2022)	8/18/2021	(2/23/2021- 6/7/2022)

Age in years, median (range)	41.5 (13-67)	50 (5-83)	37 (9-74)
Gender, n (%)			
Female	47 (52.2)	54 (55.7)	67 (72.8)
Male	43 (47.8)	42 (43.3)	25 (27.2)
No response	0 (0)	1 (1)	0 (0)
Race/ethnicity, n (%)			
Black/African American	79 (87.8)	83 (85.6)	74 (80.4)
Hispanic/Latino	8 (8.9)	11 (11.3)	3 (3.3)
White/Caucasian	1 (1.1)	1 (1)	8 (8.7)
Both Black and White	0 (0)	1 (1)	2 (2.2)
Asian-American	0 (0)	0 (0)	1 (1.1)
Other or no response	2 (2.2)	1 (1)	3 (3.3)
Education, n (%)			
High school diploma/GED or less	65 (71.4)	53 (54.6)	37 (40.2)
Post-high school	26 (28.6)	42 (43.3)	53 (57.6)
No response	0 (0)	2 (2.2)	2 (2.2)

Household members, mean (SD)	2.7	(1.4)	2.1	(1.3)	2.2	(1.2)
Household members per bedroom, mean (SD)	1	(0.5)	0.8	(0.4)	0.9	(0.5)
Primary healthcare provider, n (%) ^a						
Private doctor's office or clinic	56	(62.2)	55	(56.7)	54	(58.7)
Urgent care	15	(16.7)	23	(23.7)	17	(18.5)
Emergency room	14	(15.6)	11	(11.3)	13	(14.1)
Hospital	10	(11.1)	13	(13.4)	8	(8.7)
Free clinic	6	(6.7)	7	(7.2)	5	(5.4)
Company clinic, doctor, or nurse	6	(6.7)	1	(1)	5	(5.4)
Do not use medical care	2	(2.2)	1	(1)	0	(0)
Health insurance, n (%) ^a						
Company health insurance plan	30	(33.3)	33	(34)	56	(60.9)
Public health insurance	34	(37.8)	35	(36.1)	17	(18.5)

Private health insurance	15	(16.7)	16	(16.5)	10	(10.9)
No health insurance	12	(13.3)	15	(15.5)	8	(8.7)
Other or no response	2	(2.2)	0	(0)	1	(1.1)
Work or attend school or childcare outside the home, n (%)	85	(94.4)	44	(45.4)	41	(44.6)
Work (in person) only	82	(91.1)	41	(42.3)	37	(40.2)
Attend school only	2	(2.2)	3	(3.1)	3	(3.3)
Work and attend school	0	(0)	0	(0)	1	(1.1)
Attend childcare	1	(1.1)	0	(0)	0	(0)
Do not work or attend school or childcare outside the home, n (%)	5	(5.6)	53	(54.6)	51	(55.4)

149 ^aParticipants could select more than one option, so percentages do not sum to 100


150 Note: ILO refers to study participants living in a household with at least one adult working at an
 151 industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to
 152 participants living nearby these facilities without any known occupational exposure to livestock;
 153 Metro refers to participants living in metropolitan areas of North Carolina.

154

155 COVID-19 vaccination over time by study group

156 More Metro participants (20.7%) were up to date with COVID-19 vaccines, receiving all
157 doses in the primary series and at least one booster, compared to ILO (13.2%) or ILON (10.3%)
158 participants (Table S1). More Metro participants (55.4%) also completed the COVID-19 primary
159 vaccination series, receiving either a first dose and second dose of the Pfizer, Moderna, or
160 Novavax vaccines or a single dose of the Johnson & Johnson vaccine, compared to ILO (51.6%)
161 or ILON (48.4%) participants (Table S1). There was no statistically significant difference in time
162 to primary series completion or becoming up to date between the study groups (p-values for 3-
163 group log-rank test 0.4 and 0.1 respectively). However, among participants who received a
164 booster dose, the median date of receiving that booster dose was later for ILO (December 19,
165 2021) compared to ILON (November 3, 2021) and Metro (November 3, 2021) participants, and
166 the same pattern held for primary series completion (Figure 1).

167



168

169 **Figure 1.** Vaccination over time by study group. Origin is the date of the first FDA Emergency
170 Use Authorization for a vaccine against COVID-19 (Pfizer-BioNTech), December 11, 2020, and
171 dotted line is the date on which CDC expanded eligibility for a booster shot to all adults, November
172 19, 2021 (25).

173 *Note: ILO refers to study participants living in a household with at least one adult working at an*
 174 *industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to*
 175 *participants living nearby these facilities without any known occupational exposure to livestock;*
 176 *Metro refers to participants living in metropolitan areas of North Carolina.*

177

178 **SARS-CoV-2 IgG antibody and self-reported COVID-19 outcomes**

179 Most participant saliva samples tested had SARS-CoV-2 IgG antibodies (Table 2). The
 180 prevalence of infection-induced IgG (positive for both N and RBD) was higher among ILO (63%)
 181 than among ILON (42.9%) and Metro (48.7%) participants (PR=1.38; 95% CI: 1.06, 1.8). The
 182 prevalence of infection- and/or vaccination-induced IgG (positive for RBD) was similar among
 183 ILO (78.1%), ILON (63.1%), and Metro participants (77.6%). Significantly more ILO participants
 184 reported at least one and at least two COVID-19 symptoms compared to ILON and Metro
 185 participants (26). Fewer participants reported thinking they had COVID-19 than had infection-
 186 induced IgG. Even fewer participants reported they had ever tested positive for SARS-CoV-2,
 187 with the highest proportion among Metro participants (21.1%), followed by ILON (11.9%) and
 188 ILO (13.7%) participants.

189

190 **Table 2. SARS-CoV-2 antibody assay results and self-reported COVID-19 prevalence and**
 191 **prevalence ratios by study group**

Outcome	No. pos/total (%)	Crude PR (95% CI)
Antibody assay results		
SARS-CoV-2 infection-induced IgG (positive for both N and RBD)		
ILO vs.	46/73 (63)	
ILON (ref)	36/84 (42.9)	1.47 (1.05, 2.07)

	Metro (ref)	37/76 (48.7)	1.29 (0.95, 1.76)
	ILON and Metro (ref)	73/160 (45.6)	1.38 (1.06, 1.8)
SARS-CoV-2 infection- and/or vaccination-			
induced IgG (positive for RBD)			
	ILO vs.	57/73 (78.1)	
	ILON (ref)	53/84 (63.1)	1.24 (1, 1.53)
	Metro (ref)	59/76 (77.6)	1.01 (0.85, 1.19)
	ILON and Metro (ref)	112/160 (70)	1.12 (0.95, 1.31)
Self-reported COVID-19			
At least one symptom of COVID-19 ^a			
	ILO vs.	48/73 (65.8)	
	ILON (ref)	40/84 (47.6)	1.38 (1.03, 1.85)
	Metro (ref)	39/76 (51.3)	1.28 (0.96, 1.71)
	ILON and Metro (ref)	79/160 (49.4)	1.33 (1.05, 1.7)
At least two symptoms of COVID-19 ^a			
	ILO vs.	40/73 (54.8)	
	ILON (ref)	29/84 (34.5)	1.59 (1.08, 2.33)
	Metro (ref)	35/76 (46.1)	1.19 (0.85, 1.67)
	ILON and Metro (ref)	64/160 (40)	1.37 (1.02, 1.84)
Ever thought you had COVID-19			
	ILO vs.	19/73 (26)	
	ILON (ref)	16/84 (19)	1.37 (0.76, 2.47)
	Metro (ref)	16/76 (21.1)	1.24 (0.67, 2.28)
	ILON and Metro (ref)	32/160 (20)	1.3 (0.78, 2.17)
Ever tested positive for SARS-CoV-2			

ILO vs.	10/73 (13.7)	
ILON (ref)	10/84 (11.9)	0.96 (0.45, 2.02)
Metro (ref)	16/76 (21.1)	0.67 (0.34, 1.29)
ILON and Metro (ref)	26/160 (16.2)	0.78 0.42, 1.45)

192 ^aListed by CDC: fever or chills; cough; shortness of breath or difficulty breathing; lack of energy
 193 or general tired feeling; muscle or body aches; headache; new loss of taste or smell; sore
 194 throat, congestion, or runny nose; feeling sick to your stomach or vomiting, diarrhea; abdominal
 195 pain; skin rash (26); since February 1, 2020

196 Note: ILO refers to study participants living in a household with at least one adult working at an
 197 industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to
 198 participants living nearby these facilities without any known occupational exposure to livestock;
 199 Metro refers to participants living in metropolitan areas of North Carolina.

200

201 *SARS-CoV-2 infection-induced IgG prevalence by participant characteristics*

202 The proportion of participants with salivary SARS-CoV-2 infection-induced IgG increased
 203 over the study period (Table 3). Several participant demographic characteristics and infection
 204 prevention behaviors were associated with infection-induced IgG prevalence. The strongest
 205 association was for participants who reported generally wearing a mask in public in the past two
 206 weeks. Participants who reported not wearing a mask had significantly higher infection-induced
 207 IgG prevalence (78.6%) compared to participants who reported wearing a mask (49.3%)
 208 (PR=1.59; 95% CI: 1.19, 2.13). Participants with greater than a high school education had
 209 significantly lower infection-induced IgG prevalence (38.1%) compared to participants with a
 210 high school education or less (60.2%) (PR=0.63, 95% CI:0.48, 0.84). Participants who lived in
 211 households with more than one person per bedroom had significantly higher infection-induced
 212 IgG prevalence (69.4%) compared to participants in households with one person or fewer per
 213 bedroom (46.4%) (PR=1.5, 95% CI:1.15, 1.95). Hispanic/Latino participants had significantly

214 higher infection-induced IgG prevalence (72.7%) compared to Black participants (49.7%)
215 (PR=1.46; 95% CI: 1.1, 1.94). Only 16.7% of White participants had infection-induced IgG.
216 Reduced contact with people outside the home was associated with reduced infection-induced
217 IgG prevalence.

218 Participants' COVID-19 symptoms and health history also corresponded with SARS-
219 CoV-2 IgG. Participants who reported ever testing positive for SARS-CoV-2 had significantly
220 higher infection-induced IgG prevalence (86.1%) compared to those who reported never testing
221 positive (45%) (OR 7.58; 95% CI: 2.74, 20.9). While participants' report of at least one or at
222 least two COVID-19 symptoms listed by the CDC were not associated with infection-induced
223 IgG prevalence, participants who thought they had COVID-19 had higher infection-induced IgG
224 prevalence (70.6%) compared with participants who thought they had not (44.5%) (PR=1.59,
225 95% CI: 1.24, 2.03). Participants who reported fever plus cough or sore throat had higher
226 infection-induced IgG prevalence (68.3%) compared to those who did not (46.8%) (27)
227 (PR=1.46, 95% CI: 1.12, 1.89). Almost half (46.6%) of participants who reported a chronic
228 medical condition listed by CDC as increasing the risk of getting very sick with COVID-19 had
229 infection-induced IgG (28).

230 The highest correlation between factors associated with SARS-CoV-2 infection-induced
231 IgG indicative of infection was between date quartile and vaccination status (Cramer's v-test
232 value 0.42), followed by date and study group (0.39), group and education level (0.25), group
233 and household members per bedroom (0.23), and date and level of contact with people outside
234 the home (0.34) (Figure S1).

235

236 **Table 3.** SARS-CoV-2 infection-induced IgG prevalence and prevalence ratios (PR) and 95%
237 confidence intervals (CI) by participant characteristics, North Carolina, USA, 2021-2022.

Characteristic	No. pos./total (%)	PR	(95% CI)
----------------	--------------------	----	----------

Sampling date, quartiles			
2/23-21-4/30/21	14/59 (23.7)	Ref	
4/30/21-9/6/21	23/58 (39.7)	1.67	(0.87, 3.22)
9/6/21-3/11/22	37/58 (63.8)	2.69	(1.49, 4.84)
3/11/22-7/18/22	45/58 (77.6)	3.27	(1.85, 5.79)
Sociodemographic characteristics			
Age in years, quartiles			
5-27	27/58 (46.6)	Ref	
27-41	28/58 (48.3)	1.04	(0.71, 1.51)
42-55	35/57 (61.4)	1.32	(0.93, 1.86)
55-83	27/57 (47.4)	1.02	(0.68, 1.54)
Sex			
Female	72/139 (51.8)	Ref	
Male	47/94 (50)	0.97	(0.76, 1.23)
Race/ethnicity			
Black	99/199 (49.7)	Ref	
Hispanic/Latino	16/22 (72.7)	1.46	(1.1, 1.94)
White	1/6 (16.7)	0.34	(0.05, 2.14)
Other	3/6 (50)	1.01	(0.45, 2.27)
Education			
<= high school	80/133 (60.2)	Ref	
> high school	37/97 (38.1)	0.63	(0.48, 0.84)
Household members per bedroom			
<= 1 person per bedroom	84/181 (46.4)	Ref	

> 1 person per bedroom	34/49 (69.4)	1.50	(1.15, 1.95)
Work in person outside the home			
No	44/97 (45.4)	Ref	
Yes	75/136 (55.1)	1.22	(0.93, 1.59)
Work in meatpacking			
No	109/257 (42.4)	Ref	
Yes	10/23 (43.5)	0.98	(0.61, 1.57)
Infection prevention behaviors			
Reduced contact with people outside your home			
Yes, all household members	89/178 (50)	Ref	
Yes, some but not all household members	12/17 (70.6)	1.41	(1, 2)
No	13/18 (72.2)	1.44	(1.04, 2)
Avoiding or cancelling travel or vacation plans			
Yes	85/170 (50)	Ref	
No	33/61 (54.1)	1.08	(0.82, 1.43)
Wearing a mask when out in public			
Yes	108/219 (49.3)	Ref	
No	11/14 (78.6)	1.59	(1.19, 2.13)
Washing hands/using hand sanitizer more frequently			
Yes	112/221 (50.7)	Ref	
No	6/10 (60)	1.18	(0.7, 1.99)
COVID-19 symptoms and health history			

Ever tested positive for SARS-CoV-2 [OR because log-binomial model failed to converge]		
No	45/100 (45)	Ref
Yes	31/36 (86.1)	7.58 (2.74, 20.9)
At least one symptom of COVID-19 ^a		
No	52/106 (49.1)	Ref
Yes	67/127 (52.8)	1.08 (0.83, 1.39)
At least two symptoms of COVID-19 ^a		
No	62/129 (48.1)	Ref
Yes	57/104 (54.8)	1.14 (0.88, 1.47)
Ever thought you had COVID-19		
No	77/173 (44.5)	
Yes	36/51 (70.6)	1.59 (1.24, 2.03)
Fever with a cough at the same time or fever with a sore throat at the same time ^b (past year)		
No	89/190 (46.8)	Ref
Yes	28/41 (68.3)	1.46 (1.12, 1.89)
At least one chronic condition associated with severe illness from COVID-19 ^c		
No	64/162 (39.5)	Ref
Yes	55/118 (46.6)	1.25 (0.97, 1.61)

238 ^aListed by CDC: fever or chills; cough; shortness of breath or difficulty breathing; lack of energy
 239 or general tired feeling; muscle or body aches; headache; new loss of taste or smell; sore
 240 throat, congestion, or runny nose; feeling sick to your stomach or vomiting, diarrhea; abdominal
 241 pain; skin rash (26); since February 1, 2020

242 ^bCDC definition of influenza-like illness (27)


243 *°Listed by CDC: diabetes, cardiovascular disease, hypertension, immunocompromised*
244 *condition, autoimmune disease, cancer, chronic kidney disease, asthma, COPD, other chronic*
245 *lung disease, sickle cell anemia, depression, other mental health disorder (28)*

246

247 *SARS-CoV-2 infection-induced IgG prevalence compared to other southern US cohorts*

248 The prevalence of SARS-CoV-2 infection-induced IgG was significantly higher in the ILO
249 group of our study population compared to two other southern US cohorts sampled at times
250 overlapping the enrollment and interview dates of our cohort. Infection-induced IgG prevalence
251 was significantly higher in the ILO group of our study population sampled between March 2021
252 and July 2022 (63%) compared to the COVID-19 Prevention in Emory Healthcare Personnel
253 (COPE) Study cohort sampled between January and December 2021 (23.2%) using the same
254 salivary multiplex assay (PR=2.45, 95% CI: 1.80, 3.33) (M. H. Collins and C. D. Heaney,
255 correspondence) (29, 30) (Figure 2). Infection-induced IgG prevalence was also significantly
256 higher in the ILO group of our study population (63%) compared to the MURDOCK Cabarrus
257 County COVID-19 Prevalence and Immunity (C3PI) Study cohort, representative of Cabarrus
258 County, North Carolina, sampled March and monthly June through November 2021, using blood
259 testing with the Abbot Alinity N IgG assay (5.9% to 9.9%; PR range 6.37 to 10.67) (L. K. Newby
260 and D. Wixted, correspondence) (31).

261



262

263 **Figure 2.** SARS-CoV-2 infection-induced IgG prevalence ratios (PRs) among ILO household
 264 group participants (during Apr 2021-Jul 2022) in this study compared to other southern US
 265 reference populations.

266 Note: ILO refers to study participants living in a household with at least one adult working at an
 267 industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to
 268 participants living nearby these facilities without any known occupational exposure to livestock;
 269 Metro refers to participants living in metropolitan areas of North Carolina; Cabarrus refers to
 270 C3PI Cabarrus County, NC general population-representative cohort; Atlanta HCW refers to
 271 Emory COPE health care worker cohort.

272

273 DISCUSSION

274 We measured salivary SARS-CoV-2 IgG prevalence among 279 participants, 94% of
 275 whom were Black or Hispanic/Latino, underrepresented groups in SARS-CoV-2 seroprevalence
 276 surveys. To our knowledge, this study presents the first estimates of SARS-CoV-2 infection-
 277 induced antibody prevalence among industrial livestock operation (ILO) workers and their
 278 household members, which we observed to be high (63%) compared to participants with no
 279 household members working at industrial livestock operation (45.6%) (Table 2). This is

280 consistent with research connecting the agricultural sector and meatpacking facilities with
281 COVID-19 transmission among workers, and connecting meatpacking facilities with
282 transmission in nearby communities (10, 12, 13, 32). However, neither work at a meatpacking
283 facility nor work in person outside the home were associated with elevated prevalence of SARS-
284 CoV-2 infection-induced IgG in our study population (Table 3), and participants living in areas of
285 high industrial livestock operation intensity did not have a higher prevalence (42.9%) compared
286 to metropolitan-area participants (48.7%) (Table 2). This may be due to the relatively small
287 number of meatpacking workers (n=23) and relatively large number of participants with other
288 high-COVID-19-risk jobs and factors (e.g., low income and communities of color). Another
289 contributing factor could be case rate convergence over time between high intensity livestock
290 operation areas and metro areas. As the prevalence of COVID-19 increased in summer and fall
291 2020, the importance of any single transmission route decreased; also, if many meatpacking
292 workers and nearby residents were infected earlier on, those communities might have a greater
293 rate of at least temporary immunity (32). Our group definitions of ILO, ILON, and Metro also
294 collapse many differences that have been connected to exposure to SARS-CoV-2 and COVID-
295 19: time, age, sex, race/ethnicity, education, and urbanicity, among others (14–16).

296 Self-reported symptoms of COVID-19 were also higher in the ILO compared to
297 combined ILO and Metro groups (Table 2). This could be because of more COVID-19 cases,
298 though some contribution could also be from other health effects related to industrial livestock
299 production and processing work. Hog and poultry production work have been associated with
300 respiratory and infectious disease broadly, and processing work has also been associated with
301 respiratory, infectious, and skin disease, which overlap with almost all COVID symptoms listed
302 by CDC (6, 26, 33, 34). While 51% of participants overall had SARS-CoV-2 infection-induced
303 IgG, less than half reported thinking they had COVID-19, and only 15.4% reported ever testing
304 positive for COVID-19 (Table 2). Of participants who tested positive for infection-induced IgG,
305 68% did not think they had COVID-19 (Table 3). This is a higher proportion compared to the

306 estimated prevalence of asymptomatic infections among people with confirmed COVID-19, 40-
307 45% (35). Participants might have attributed any symptoms to other health issues, including
308 some related to ILO work or residence near ILOs. The lower percentage of people ever testing
309 positive for COVID-19 even compared to the low percentage of people who thought they had
310 COVID also underlines the importance of accessible COVID-19 testing.

311 A higher proportion of Metro compared to ILO or ILON participants completed the
312 primary vaccination series and received at least one booster, although the difference between
313 groups was not statistically significant, and the groups had similar SARS-CoV-2 infection-
314 and/or vaccination-induced IgG (positive for RBD) (Figure 1, Table 2). Among participants who
315 completed the primary vaccination series, the median date of completion was later for ILO
316 compared to ILON and Metro participants, and the same pattern held for booster doses (Figure
317 1). Although the differences in vaccination timing between groups were not statistically
318 significant, these delays are notable because of the spread of the more-contagious Delta and
319 Omicron variants in summer and winter 2021, respectively (36). Because a greater proportion of
320 ILO participants had a high school education or less, our results are also consistent with
321 evidence of vaccination disparities by social class, and with evidence that vaccination coverage
322 increased most during spring and summer 2021 among people with lower education and
323 income (37).

324 COVID-19 vaccination rates in our study population were lower than the US and North
325 Carolina general populations. The proportion of our study population (ILO, ILON, and Metro
326 combined) who completed the initial vaccination protocol (52%) was lower than the proportion of
327 North Carolina (62.9%) and US residents (67.2%) vaccinated at the last date of follow-up, July
328 18, 2022 (38) (Table S1). However, participants may have become vaccinated after their initial
329 or follow-up call; the proportion of participants who had completed the initial vaccination protocol
330 by the median initial or follow-up call date was 50.7%, closer to the proportion of North Carolina
331 (57.3%) and the US (62.6%) at that date, January 10, 2022. The proportion of our cohort who

332 received at least one booster dose was also lower compared to North Carolina and the US at
333 the end of the study, but similar at the median follow-up date (38). Although our modest sample
334 size and timing of initial and follow-up call complicate comparison to North Carolina and the US,
335 our results support the importance of dismantling vaccination barriers, especially for ILO
336 workers, their household members, and rural communities.

337 The proportion of participants with SARS-CoV-2 infection-induced IgG prevalence
338 increased over the course of the study (Table 3). This is consistent with the spread of the virus
339 over time and trends in other seroprevalence surveys (24, 39). Among health behaviors
340 assessed, wearing a mask had the highest protective effect (Table 3). This is consistent with
341 cohort, ecological, and modelling studies on the efficacy of masks for COVID-19 protection (40).
342 Reporting mask use could also be an indicator of other modifiable and non-modifiable risk
343 factors. We did not ask about the frequency of mask use overall, mask use in particular contexts
344 that might be higher risk transmission settings, or about the type(s) of masks participants used,
345 all of which affect any relationship between mask use and SARS-CoV-2 exposure.

346 Education level and ethnicity were also associated with SARS-CoV-2 infection-induced
347 IgG. A study of the joint effects of socioeconomic position estimated by education level,
348 race/ethnicity, and gender on COVID-19 mortality among working-age adults found the same
349 trends of higher COVID-19 mortality for low vs. high socioeconomic position adults and for Black
350 and Hispanic/Latino vs. White adults (41). Our results are also consistent with elevated rates of
351 infection-induced seroprevalence among Hispanic/Latino and Black compared with White blood
352 donors across the US (24) and elevated infection-induced seroprevalence among
353 Hispanic/Latino and Black North Carolina residents in surveillance based on hospital remnant
354 blood samples (16), as well as with disproportionate numbers of cases and deaths among
355 Hispanic/Latino, Native American, and Black communities (14). People with fewer
356 socioeconomic resources are less able to use different strategies to avoid exposure to SARS-
357 CoV-2 and more likely to work in crowded occupations or occupations with contact with the

358 public (42). Under racialized capitalism, Hispanic/Latino, Indigenous, and Black workers face
359 occupational status disadvantages even within specific jobs (42, 43).

360 We found that participants with more than one person per household bedroom had
361 higher prevalence of SARS-CoV-2 infection-induced IgG (Table 3). Living in more crowded
362 conditions could increase exposures to SARS-CoV-2 from household members. Level of
363 contact with people outside of the home was also associated with higher infection-induced IgG
364 prevalence (Table 3). A systematic review of observational studies of SARS-CoV-2 and the
365 betacoronaviruses that cause severe acute respiratory syndrome (SARS-CoV-1) and Middle
366 east respiratory syndrome (MERS) found reduced transmission of viruses with physical
367 distancing of 1m or more as well as with face mask usage, consistent with our results (44).

368 Participants' COVID-19 health history and symptoms also corresponded with SARS-
369 CoV-2 IgG prevalence. Close to 90% of participants who reported ever testing positive for
370 SARS-CoV-2 had infection-induced IgG (positive for both N and RBD), compared to 45% of
371 participants who did not report ever testing positive (Table 3). Nucleocapsid (N) IgG is useful for
372 determining response to infection because these antibodies are produced in the immune
373 response to infection and not in the response to vaccines currently approved for use in the US
374 (23). However, a limitation is that N IgG half-life in the body is generally shorter compared to
375 RBD and S IgG (45). Participants who reported testing positive for SARS-CoV-2 but tested
376 negative for N IgG could have been infected longer ago and have levels of N IgG below the
377 positivity cutoff. Participants who reported thinking they had COVID-19 and participants who
378 reported influenza-like illness had a higher prevalence of infection-induced IgG compared to
379 participants who did not, although there was a similar prevalence of infection-induced IgG
380 among participants who reported at least one or at least two symptoms of COVID-19 compared
381 to those who did not (Table 3). This is consistent with relatively high proportions of
382 asymptomatic infections (35), overlap between COVID-19 and other health condition symptoms,
383 and limited durability of N IgG response.

384 We found prevalence of SARS-CoV-2 infection-induced IgG higher than in comparable
385 cohorts. Infection-induced IgG prevalence in the ILO group of our study population was more
386 than twice that in Emory University's COPE cohort of Atlanta healthcare workers sampled from
387 January to December 2021 using the same salivary multiplex assay (M. H. Collins and C. D.
388 Heaney, correspondence) (29, 30) (Figure 2). Healthcare workers are at higher risk for COVID-
389 19 compared to the general population (46, 47). High infection-induced IgG among ILO
390 participants compared to workers in another high-COVID-19-risk occupation sampled with the
391 same assay during an overlapping time period underlines the high exposures among North
392 Carolina livestock operation workers and their household members. Infection-induced IgG
393 prevalence among ILO participants was more than five times the highest prevalence observed
394 in March and monthly June through November 2021 in Duke University's Cabarrus County,
395 North Carolina general-population-representative cohort (L. K. Newby and D. Wixted,
396 correspondence) (31) (Figure 2). Infection-induced IgG prevalence was also higher in the ILO
397 group of our study population (63%) compared to nationwide serology estimates. A study of
398 blood donations estimated infection-induced seroprevalence to be 28.8% overall in December
399 2021; higher among Hispanic (40.2%) and Black (32.5%) donors and donors living in the South
400 (33.5%) during the same time period (24). Infection-induced IgG prevalence in our cohort was
401 also generally higher compared to estimates using residual data from commercial labs across
402 the US weighted by age, sex, and metropolitan status, which ranged from 20.8% to 57.7%
403 nationally and 22.5% to 52% in North Carolina during the sixteen sampling periods that
404 overlapped our study period (36, 39) (Figure S2).

405 An important consideration for interpreting our results is our non-population-
406 representative snowball sampling strategy. Participants were volunteers recruited primarily from
407 social networks of community organizers with our partner community organization and might
408 differ in several ways from the eastern North Carolina population in general. Another
409 consideration is our enrollment period from February 2021 to July 2022, including changing

410 recommendations on vaccination and boosters, as well as increasing cases due to the more
411 contagious Delta and Omicron variants. Vaccination, exposure, and treatment options varied for
412 participants over the course of enrollment and differences over time may obscure differences by
413 study group or participant characteristics. The long enrollment period also complicates
414 comparisons with other southern US cohorts and CDC nationwide studies (Figure S2). Our
415 study also has limitations associated with antibody test characteristics. Our multiplex assay was
416 optimized for specificity over sensitivity, so we may have missed a proportion of infection-
417 induced and vaccination or infection-induced antibody responses among our participants,
418 especially for those infected a longer time ago who may have sero-reverted. The half-life of
419 SARS-CoV-2 N IgG using our assay was about 64 days, compared to RBD about 100 days
420 (45). Because we sampled participants through July 18, 2022, 910 days after the first confirmed
421 case in the US, we likely underestimated infection-induced SARS-CoV-2 exposure.

422 Our findings show high rates of SARS-CoV-2 infection-induced IgG in a predominantly
423 rural, Black, and Hispanic/Latino North Carolina cohort, especially among industrial livestock
424 operation workers and their families. We add to reports of high numbers of cases associated
425 with meatpacking facilities early in the course of the pandemic and to evidence of health
426 disparities in exposure to SARS-CoV-2 by socioeconomic position. Delays in the timing of
427 receipt of COVID-19 vaccination reinforce the importance of dismantling vaccination barriers,
428 especially for industrial livestock operation workers and their household members. Associations
429 between masking and physical distancing with antibody results also add to evidence of the
430 effectiveness of these prevention strategies.

431

432 **MATERIALS AND METHODS**

433 *Study design and participants*

434 This study was designed and conducted in partnership with REACH. Data were
435 collected by REACH community organizers and researchers from Johns Hopkins Bloomberg

436 School of Public Health (JHSPH). Using a snowball sampling approach, REACH community
437 organizers recruited ILO, ILON, and metro-area households. All enrolled households had at
438 least one adult (≥ 18 years old) enrolled into the study. In addition to the one adult, all additional
439 household members of any age were eligible to be enrolled. Eligibility criteria for all groups also
440 included ability to understand spoken English or Spanish and access to household phone or
441 mobile device and refrigerator. The study was developed in collaboration between JHSPH and
442 REACH. The JHSPH Institutional Review Board (IRB) approved this study (IRB00014420).

443

444 *Questionnaire data and saliva sample collection*

445 Before participation, adult participants provided oral consent. For children 0-6 years old,
446 a parent or legal guardian provided permission, oral assent, and questionnaire responses for
447 the child. For children 7-17 years old, a parent/legal guardian provided permission for the child
448 and the child provided oral assent and questionnaire responses, with parents answering some
449 questions as appropriate (e.g., health history). Recruitment, consent, questionnaires, and saliva
450 self-collection were conducted remotely via video or phone call, without physical contact
451 between study team and participants. Questionnaire responses were recorded and training and
452 supervision of biospecimen self-collection were provided during the same video or phone call.
453 Participants and parents or legal guardians of children 0-6 reported demographic information;
454 work, school, or childcare outside the home; infection prevention behaviors; and health history,
455 including information related to COVID-19 vaccination and symptoms consistent with COVID-
456 19. Participants who worked at an ILO were also asked more detailed questions about livestock
457 production and processing activities. Study questionnaires were developed in collaboration with
458 REACH organizers. REACH interviewers included those fluent in English and Spanish, and
459 participants had the ability to respond in either language. REACH and JHSPH interviewers
460 recorded participant responses in REDCap, a secure web application for managing online
461 surveys (48, 49).

462 After consent, all enrolled households received a study package containing all materials
463 for saliva self-collection, self-collection procedure information, and packaging materials via
464 REACH drop-off or direct shipping. During the questionnaire, training, and sampling call,
465 REACH or JHSPH interviewers instructed all enrolled participants on how to collect saliva
466 samples and stayed on the call as participants collected samples to answer any questions and
467 ascertain if participants followed procedures. All participants provided two self-collected saliva
468 samples: an oral fluid saliva sample and a passive drool saliva sample. For the oral fluid
469 sample, participants brushed the Oracol+ 2.0 saliva collection device (Malvern Medical
470 Developments, Worcester, United Kingdom) along their gums for 1-2 minutes. Participants were
471 instructed to store their samples in a refrigerator until pickup by a REACH courier or direct
472 shipping to JHSPH. Because booster vaccination was recommended by the CDC during the
473 course of our study, we added questions about this topic mid-study and recontacted participants
474 not initially asked.

475

476 *Multiplex SARS-CoV-2 IgG assay for oral fluid*

477 Oral fluid samples were separated from sponges by centrifugation and tested for SARS-
478 CoV-2 nucleocapsid (N), receptor-binding domain (RBD), and spike (S) IgG, using a multiplex
479 bead-based immunoassay based on Luminex technology, which has been described previously
480 (N. Pisanic, A. Antar, K. Kruczynski, M. G. Rivera, K. Spicer, P. R. Randad, A. Pekosz, S. L.
481 Klein, M. J. Betenbaugh, B. Detrick, W. Clarke, D. L. Thomas, Y. C. Manabe, and C. D. Heaney,
482 submitted for publication) (19, 20). Briefly, the multiplex assay included SARS-CoV-2 N, RBD,
483 and S antigens coupled to magnetic microparticles, and a background control bead coated with
484 bovine serum albumin (BSA). Saliva samples were centrifuged for 5 min at 10,000 g and 10 μ L
485 supernatant were added to a 96-well assay plate containing 40 μ L bead mix (1,000 beads per
486 bead set) in assay buffer (PBS-TBN). After incubation to allow for binding of SARS-CoV-2
487 specific IgG present in saliva samples, beads were washed, and fluorophore-labeled anti-

488 human IgG was added to the plate. After a second incubation to allow for binding of labeled
489 anti-IgG to salivary IgG on the beads, the plate was washed again, and median fluorescent
490 intensity (MFI) was read on a Luminex MagPix instrument.

491 To determine optimum performance cutoffs for infection-induced IgG, we used 1320
492 saliva samples from individuals without known prior exposure to the SARS-CoV-2 virus or
493 vaccine (presumed negatives) and 325 saliva samples collected >14 days after symptom onset
494 of a molecularly confirmed SARS-CoV-2 infection (infection-induced positives). To determine
495 optimum performance cutoffs for infection- and/or vaccination-induced IgG, we used 1002 saliva
496 samples from individuals without known prior exposure to the SARS-CoV-2 virus or vaccine
497 (presumed negatives) and 492 saliva samples collected >14 days after symptom onset of a
498 molecularly confirmed SARS-CoV-2 infection and/or >14 days after completing the primary
499 COVID-19 vaccination series (infection- and/or vaccination-induced positives). We first
500 subtracted the BSA signal from all SARS-CoV-2 signals. The best algorithm for infection-
501 induced IgG relied on N (Cat. No. Z03480, Genscript, NJ, USA) and RBD (Cat. No. 40592-
502 V08H, Sino Biological, Beijing, China) (sensitivity=97.6%, specificity=99.4%) and the best
503 algorithm for infection- and/or vaccination-induced IgG response relied on RBD (Cat. No.
504 40592-V08H, Sino Biological, Beijing, China) (sensitivity=99.4%, specificity=99.3%).

505

506 *Data from other southern US cohorts*

507 Seropositivity data from the COVID-19 Prevention in Emory Healthcare Personnel
508 (COPE) Study cohort were obtained through correspondence (M. H. Collins and C. D. Heaney,
509 correspondence). Participants were health care providers recruited from 4 university-affiliated
510 hospitals and clinics in Atlanta, Georgia, and saliva samples for serology were collected at
511 enrollment, at 3 months, and at 6 months. Oral fluid saliva samples were tested with the
512 multiplex assay described above, as in our North Carolina study population (19, 20, 29, 30).
513 Monthly seropositivity and N seropositivity data from the Cabarrus County COVID-19

514 Prevalence and Immunity (C3PI) were also obtained through correspondence (L. K. Newby and
515 D. Wixted, correspondence). Participants were selected from a larger ongoing cohort study
516 through a weighted, randomized scheme to approximate the sex, age, and race/ethnicity of
517 Cabarrus County, North Carolina. Blood samples for serology were collected monthly, and
518 serology testing was performed with the Abbott Alinity IgG N protein antibody assay (specificity
519 99.9% and sensitivity 100%) (31). Nationwide and North Carolina infection-induced antibody
520 seroprevalence estimates from CDC commercial laboratory surveys were downloaded from
521 <https://covid.cdc.gov/covid-data-tracker/#national-lab> (36).

522

523 *Statistical analysis*

524 We first compared the distribution of demographic characteristics and potential risk
525 factors for SARS-CoV-2 IgG among the ILO household, ILON household, and metropolitan area
526 (Metro) household groups. Using participants' reported dates of receiving a first dose, receiving
527 a second dose (or first dose for the Janssen [Johnson & Johnson]), and receiving a booster
528 dose of the COVID-19 vaccine, we plotted time to each vaccination event by group and tested
529 for difference in time to each vaccination event by group using the 3-group log-rank test
530 implemented in *survdiff* function (*survival* package) in R. Next, we calculated the crude
531 prevalence of salivary SARS-CoV-2 IgG outcomes in each household group (ILO, ILON, and
532 Metro), and the crude prevalence of infection-induced IgG across levels of participant
533 characteristics. For SARS-CoV-2 IgG and self-reported COVID-19 outcomes, we used
534 generalized estimating equation (GEE) log-binomial regression models clustered by household
535 to calculate crude prevalence ratios (PRs) and 95% confidence intervals (CIs) comparing
536 outcome prevalence among the ILO versus the ILON, Metro, and combined ILON and Metro
537 groups. We also used GEE log-binomial regression models to calculate crude prevalence ratios
538 of infection-induced IgG by participant characteristics, with the category with the greatest
539 number of participants as the reference group. To compare infection-induced IgG prevalence in

540 our cohort to other southern US cohorts, we used log-binomial regression models to calculate
541 crude prevalence ratios between the ILO group versus the ILON, Metro, and other southern US
542 cohort groups with enrollment dates overlapping at least one day of our enrollment date range.
543 All statistical analyses were completed in R 2022.02.0 (50).

544

545 REFERENCES

- 546 1. USDA. 2022. Annual Statistical Bulletin. USDA National Agricultural Statistics Service,
547 North Carolina Field Office.
548 https://www.nass.usda.gov/Statistics_by_State/North_Carolina/Publications/Annual_Statistical_Bulletin/index.php. Retrieved 12 April 2022.
549
- 550 2. Azaroff LS, Levenstein C, Wegman DH. 2002. Occupational injury and illness surveillance:
551 conceptual filters explain underreporting. *Am J Public Health* 92:1421–1429.
- 552 3. Leigh JP, Du J, McCurdy SA. 2014. An estimate of the U.S. government’s undercount of
553 nonfatal occupational injuries and illnesses in agriculture. *Annals of Epidemiology* 24:254–
554 259.
- 555 4. Ceryes CA, Heaney CD. 2019. “Ag-gag” laws: evolution, resurgence, and public health
556 implications. *New Solutions: A Journal of Environmental and Occupational Health Policy*
557 28:664–682.
- 558 5. BLS. Incidence rates of nonfatal occupational injuries and illnesses by industry and case
559 types, 2020. US Bureau of Labor Statistics: Injuries, Illnesses, and Fatalities.
560 https://www.bls.gov/iif/oshwc/osh/os/summ1_00_2020.htm. Retrieved 5 October 2022.
- 561 6. Donham KJ. 2010. Community and occupational health concerns in pork production: a
562 review. *Journal of Animal Science* 88:E102–E111.

- 563 7. Wing S, Wolf S. 2000. Intensive livestock operations, health, and quality of life among
564 eastern North Carolina residents. *Environmental Health Perspectives* 108:6.
- 565 8. Cole D, Todd L, Wing S. 2000. Concentrated swine feeding operations and public health: a
566 review of occupational and community health effects. *Environ Health Perspect* 108:685–
567 699.
- 568 9. Dyal JW, Grant MP, Broadwater K, Bjork A, Waltenburg MA, Gibbins JD, Hale C, Silver M,
569 Fischer M, Steinberg J, Basler CA, Jacobs JR, Kennedy ED, Tomasi S, Trout D, Hornsby-
570 Myers J, Oussayef NL, Delaney LJ, Patel K, Shetty V, Kline KE, Schroeder B, Herlihy RK,
571 House J, Jervis R, Clayton JL, Ortbahn D, Austin C, Berl E, Moore Z, Buss BF, Stover D,
572 Westergaard R, Pray I, DeBolt M, Person A, Gabel J, Kittle TS, Hendren P, Rhea C,
573 Holsinger C, Dunn J, Turabelidze G, Ahmed FS, deFijter S, Pedati CS, Rattay K, Smith
574 EE, Luna-Pinto C, Cooley LA, Saydah S, Preacely ND, Maddox RA, Lundeen E, Goodwin
575 B, Karpathy SE, Griffing S, Jenkins MM, Lowry G, Schwarz RD, Yoder J, Peacock G,
576 Walke HT, Rose DA, Honein MA. 2020. COVID-19 among workers in meat and poultry
577 processing facilities — 19 states, April 2020. *MMWR Morb Mortal Wkly Rep* 69.
- 578 10. Waltenburg MA, Victoroff T, Rose CE, Butterfield M, Jervis R, Fedak K, Gabel JA,
579 Feldpausch A, Dunne EM, Austen C, Ahmed FS, Tubach S, Rhea C, Krueger A, Crum DA,
580 Vostok J, Moore MJ, Turabelidze G, Stover D, Donahue M, Edge K, Gutierrez B, Kline KE,
581 Martz N, Cummins J, Barbeau B, Murphy J, Darby B, Graff NR, Dostal TKH, Pray IW,
582 Tillman C, Dittrich MM, Burns-Grant G, Lee S, Spieckerman A, Iqbal K, Griffing SM,
583 Lawson A, Mainzer HM, Bealle AE, Edding E, Arnold KE, Rodriguez T, Merkle S, Pettrone
584 K, Schlanger K, LaBar K, Hendricks K, Lasry A, Krishnasamy V, Walke HT, Rose DA,
585 Honein MA, COVID-19 Response Team. 2020. Update: COVID-19 among workers in meat

- 586 and poultry processing facilities — United States, April–May 2020. *MMWR Morb Mortal*
587 *Wkly Rep* 69:887–892.
- 588 11. 2021. House Select Subcommittee on the Coronavirus Crisis: How The Meatpacking
589 Industry Failed the Workers Who Feed America. Staff Memorandum. Washington, DC.
590 [https://coronavirus.house.gov/sites/democrats.coronavirus.house.gov/files/2021.10.27%20](https://coronavirus.house.gov/sites/democrats.coronavirus.house.gov/files/2021.10.27%20Meatpacking%20Report.Final_.pdf)
591 [Meatpacking%20Report.Final_.pdf](https://coronavirus.house.gov/sites/democrats.coronavirus.house.gov/files/2021.10.27%20Meatpacking%20Report.Final_.pdf).
- 592 12. Taylor CA, Boulos C, Almond D. 2020. Livestock plants and COVID-19 transmission. *Proc*
593 *Natl Acad Sci U S A* 117:31706–31715.
- 594 13. Waltenburg MA, Rose CE, Victoroff T, Butterfield M, Dillaha JA, Heinzerling A, Chuey M,
595 Fierro M, Jervis RH, Fedak KM, Leapley A, Gabel JA, Feldpausch A, Dunne EM, Austin C,
596 Pedati CS, Ahmed FS, Tubach S, Rhea C, Tonzel J, Krueger A, Crum DA, Vostok J,
597 Moore MJ, Kempfer H, Scheftel J, Turabelidze G, Stover D, Donahue M, Thomas D, Edge
598 K, Gutierrez B, Berl E, McLafferty M, Kline KE, Martz N, Rajotte JC, Julian E, Diedhiou A,
599 Radcliffe R, Clayton JL, Ortbahn D, Cummins J, Barbeau B, Carpenter S, Pringle JC,
600 Murphy J, Darby B, Graff NR, Dostal TKH, Pray IW, Tillman C, Rose DA, Honein MA.
601 2021. Coronavirus Disease among Workers in Food Processing, Food Manufacturing, and
602 Agriculture Workplaces. *Emerging Infectious Diseases* 27:243–249.
- 603 14. Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. 2021. The Disproportionate Impact of
604 COVID-19 on Racial and Ethnic Minorities in the United States. *Clinical Infectious*
605 *Diseases* 72:703–706.
- 606 15. Zalla LC, Martin CL, Edwards JK, Gartner DR, Noppert GA. 2021. A Geography of Risk:
607 Structural Racism and COVID-19 Mortality in the United States. *American Journal of*
608 *Epidemiology* 190:1439–1446.

- 609 16. Lopez CA, Cunningham CH, Pugh S, Brandt K, Vanna UP, Delacruz MJ, Guerra Q,
610 Bhowmik DR, Goldstein SJ, Hou YJ, Gearhart M, Wiethorn C, Pope C, Amditis C, Pruitt K,
611 Newberry-Dillon C, Schmitz JL, Premkumar L, Adimora AA, Baric RS, Emch M, Boyce RM,
612 Aiello AE, Fosdick BK, Larremore DB, de Silva AM, Juliano JJ, Markmann AJ. 2022.
613 Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in
614 Central North Carolina from April to December 2020. *mSphere* 7:e0084121.
- 615 17. CDC. 2020. Cases, Data, and Surveillance. Centers for Disease Control and Prevention.
616 [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html)
617 [discovery/hospitalization-death-by-race-ethnicity.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html). Retrieved 11 March 2021.
- 618 18. Sherman AC, Smith T, Zhu Y, Taibl K, Howard-Anderson J, Landay T, Pisanic N,
619 Kleinhenz J, Simon TW, Espinoza D, Edupuganti N, Hammond S, Roupheal N, Shen H,
620 Fairley JK, Edupuganti S, Cardona-Ospina JA, Rodriguez-Morales AJ, Premkumar L,
621 Wrammert J, Tarleton R, Fridkin S, Heaney CD, Scherer EM, Collins MH. 2021.
622 Application of SARS-CoV-2 Serology to Address Public Health Priorities. *Front Public*
623 *Health* 9:744535.
- 624 19. Heaney CD, Pisanic N, Randad PR, Kruczynski K, Zhu X, Littlefield K, Patel EU, Shrestha
625 R, Shoham S, Sullivan D, Gebo K, Hanley D, Quinn TC, Casadevall A, Zenilman JM,
626 Pekosz A, Bloch EM, Tobian AAR. Comparative performance of multiplex salivary and
627 commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization
628 titers 25.
- 629 20. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, Klein SL,
630 Betenbaugh MJ, Clarke WA, Laeyendecker O, Caturegli PP, Larman HB, Detrick B, Fairley
631 JK, Sherman AC, Roupheal N, Edupuganti S, Granger DA, Granger SW, Collins MH,

- 632 Heaney CD. 2020. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific
633 Antibody Responses in Saliva. *J Clin Microbiol* 59.
- 634 21. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, Raeber ME,
635 Adamo S, Weigang S, Emmenegger M, Hasler S, Bosshard PP, De Cecco E, Bächli E,
636 Rudiger A, Stüssi-Helbling M, Huber LC, Zinkernagel AS, Schaer DJ, Aguzzi A, Kochs G,
637 Held U, Probst-Müller E, Rampini SK, Boyman O. 2021. Systemic and mucosal antibody
638 responses specific to SARS-CoV-2 during mild versus severe COVID-19. *J Allergy Clin*
639 *Immunol* 147:545-557.e9.
- 640 22. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. 2020. Mucosal Immunity in COVID-19:
641 A Neglected but Critical Aspect of SARS-CoV-2 Infection. *Frontiers in Immunology*
642 11:3221.
- 643 23. Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, Yan T, Cao C, Gurry C,
644 Hankins CA, Cheng MP, Gingras A-C, Mazer BD, Papenburg J, Langlois M-A. 2022.
645 Adapting Serosurveys for the SARS-CoV-2 Vaccine Era. *Open Forum Infectious Diseases*
646 9:ofab632.
- 647 24. Jones JM, Opsomer JD, Stone M, Benoit T, Ferg RA, Stramer SL, Busch MP. 2022.
648 Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates
649 Based on Blood Donations, July 2020-December 2021. *JAMA* 328:298–301.
- 650 25. CDC. 2022. CDC Museum COVID-19 Timeline. Centers for Disease Control and
651 Prevention. <https://www.cdc.gov/museum/timeline/covid19.html>. Retrieved 1 September
652 2022.

- 653 26. CDC. 2022. Coronavirus Disease 2019 (COVID-19) – Symptoms. Centers for Disease
654 Control and Prevention. [https://www.cdc.gov/coronavirus/2019-ncov/symptoms-
testing/symptoms.html](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-
655 testing/symptoms.html). Retrieved 10 August 2022.
- 656 27. CDC. 2022. Weekly U.S. Influenza Surveillance Report. Centers for Disease Control and
657 Prevention. <https://www.cdc.gov/flu/weekly/index.htm>. Retrieved 12 August 2022.
- 658 28. CDC. 2022. People with Certain Medical Conditions. Centers for Disease Control and
659 Prevention. [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-
with-medical-conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-
660 with-medical-conditions.html). Retrieved 12 August 2022.
- 661 29. Howard-Anderson JR, Adams C, Dube WC, Smith TC, Sherman AC, Edupuganti N,
662 Mendez M, Chea N, Magill SS, Espinoza DO, Zhu Y, Phadke VK, Edupuganti S, Steinberg
663 JP, Lopman BA, Jacob JT, Fridkin SK, Collins MH. 2022. Occupational risk factors for
664 severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare
665 personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory
666 Healthcare Personnel (COPE) Study. *Infect Control Hosp Epidemiol* Online ahead of
667 print:1–8.
- 668 30. Howard-Anderson JR, Adams C, Sherman AC, Dube WC, Smith TC, Edupuganti N, Chea
669 N, Magill SS, Espinoza DO, Zhu Y, Phadke VK, Edupuganti S, Steinberg JP, Lopman BA,
670 Jacob JT, Collins MH, Fridkin SK. 2022. Occupational risk factors for severe acute
671 respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A
672 cross-sectional analysis of subjects enrolled in the COVID-19 Prevention in Emory
673 Healthcare Personnel (COPE) study. *Infect Control Hosp Epidemiol* 43:381–386.
- 674 31. Neighbors CE, Wu AE, Wixted DG, Heidenfelder BL, Kingsbury CA, Register HM, Louzao
675 R, Sloane R, Eckstrand J, Pieper CC, Faldowski RA, Denny TN, Woods CW, Newby LK.

- 676 2022. The Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study: design,
677 methods, and baseline characteristics. *Am J Transl Res* 14:5693–5711.
- 678 32. Saitone TL, Aleks Schaefer K, Scheitrum DP. 2021. COVID-19 morbidity and mortality in
679 U.S. meatpacking counties. *Food Policy* 101:102072.
- 680 33. Mitloehner FM, Calvo MS. 2008. Worker health and safety in concentrated animal feeding
681 operations. *J Agric Saf Health* 14:163–187.
- 682 34. Campbell DS. 1999. Health hazards in the meatpacking industry. *Occup Med* 14:351–372.
- 683 35. Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, Wu Y, Liu M. 2021. Global Percentage of
684 Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With
685 Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. *JAMA Network*
686 *Open* 4:e2137257.
- 687 36. CDC. 2020. COVID Data Tracker. Centers for Disease Control and Prevention.
688 <https://covid.cdc.gov/covid-data-tracker>. Retrieved 7 June 2021.
- 689 37. Nguyen KH, Nguyen K, Geddes M, Allen JD, Corlin L. 2022. Trends in COVID-19
690 vaccination receipt and intention to vaccinate, United States, April to August, 2021.
691 *American Journal of Infection Control* 50:699–703.
- 692 38. State-by-state data on COVID-19 vaccinations in the United States. Our World in Data.
693 <https://ourworldindata.org/us-states-vaccinations>. Retrieved 23 August 2022.
- 694 39. Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, Lee A, Moyse D, Havers FP,
695 Harding L, Fry AM, Hall AJ, Martin K, Biel M, Deng Y, Meyer WA, Mathur M, Kyle T,
696 Gundlapalli AV, Thornburg NJ, Petersen LR, Edens C. 2021. Estimated SARS-CoV-2
697 Seroprevalence in the US as of September 2020. *JAMA Intern Med* 181:450–460.

- 698 40. Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen H-M, von Delft A, Price
699 A, Fridman L, Tang L-H, Tang V, Watson GL, Bax CE, Shaikh R, Questier F, Hernandez
700 D, Chu LF, Ramirez CM, Rimoin AW. 2021. An evidence review of face masks against
701 COVID-19. *Proceedings of the National Academy of Sciences* 118:e2014564118.
- 702 41. Pathak EB, Menard J, Garcia RB, Salemi JL. 2021. Social Class, Race/Ethnicity, and
703 COVID-19 Mortality Among Working Age Adults in the United States.
- 704 42. Pathak EB, Menard JM, Garcia RB, Salemi JL. 2022. Joint Effects of Socioeconomic
705 Position, Race/Ethnicity, and Gender on COVID-19 Mortality among Working-Age Adults in
706 the United States. *Int J Environ Res Public Health* 19:5479.
- 707 43. Paul A. Landsbergis, Joseph G. Grzywacz, Anthony D. LaMontagne. 2014. Work
708 organization, job insecurity, and occupational health disparities. *American Journal of*
709 *Industrial Medicine* 57:495–515.
- 710 44. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, Chu DK, Akl EA, El-
711 harakeh A, Bognanni A, Lotfi T, Loeb M, Hajizadeh A, Bak A, Izcovich A, Cuello-Garcia
712 CA, Chen C, Harris DJ, Borowiack E, Chamseddine F, Schünemann F, Morgano GP,
713 Schünemann GEUM, Chen G, Zhao H, Neumann I, Chan J, Khabisa J, Hneiny L, Harrison
714 L, Smith M, Rizk N, Rossi PG, AbiHanna P, El-khoury R, Stalteri R, Baldeh T, Piggott T,
715 Zhang Y, Saad Z, Khamis A, Reinap M, Duda S, Solo K, Yaacoub S, Schünemann HJ.
716 2020. Physical distancing, face masks, and eye protection to prevent person-to-person
717 transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The*
718 *Lancet* 395:1973–1987.
- 719 45. Randad PR, Pisanic N, Kruczynski K, Howard T, Rivera MG, Spicer K, Antar AAR, Penson
720 T, Thomas DL, Pekosz A, Ndahiro N, Aliyu L, Betenbaugh MJ, Manley H, Detrick B, Katz

- 721 M, Cosgrove S, Rock C, Zyskind I, Silverberg JI, Rosenberg AZ, Duggal P, Manabe YC,
722 Collins MH, Heaney CD. 2021. Durability of SARS-CoV-2-specific IgG responses in saliva
723 for up to 8 months after infection.
- 724 46. Mutambudzi M, Niedzwiedz CL, Macdonald EB, Leyland AH, Mair FS, Anderson JJ, Celis-
725 Morales CA, Cleland J, Forbes J, Gill JM, Hastie C, Ho FK, Jani BD, Mackay DF, Nicholl
726 BI, O'Donnell CA, Sattar NI, Welsh PI, Pell JP, Katikireddi SV, Demou E. 2020. Occupation
727 and risk of COVID-19: prospective cohort study of 120,621 UK Biobank participants.
728 medRxiv 2020.05.22.20109892.
- 729 47. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo C-G, Ma W, Mehta RS, Warner ET,
730 Sikavi DR, Lo C-H, Kwon S, Song M, Mucci LA, Stampfer MJ, Willett WC, Eliassen AH,
731 Hart JE, Chavarro JE, Rich-Edwards JW, Davies R, Capdevila J, Lee KA, Lochlainn MN,
732 Varsavsky T, Sudre CH, Cardoso MJ, Wolf J, Spector TD, Ourselin S, Steves CJ, Chan
733 AT, Albert CM, Andreotti G, Bala B, Balasubramanian BA, Beane-Freeman LE, Brownstein
734 JS, Bruinsma FJ, Coresh J, Costa R, Cowan AN, Deka A, Deming-Halverson SL, Elena
735 Martinez M, Ernst ME, Figueiredo JC, Fortuna P, Franks PW, Freeman LB, Gardner CD,
736 Ghobrial IM, Haiman CA, Hall JE, Kang JH, Kirpach B, Koenen KC, Kubzansky LD, Lacey,
737 Jr JV, Le Marchand L, Lin X, Lutsey P, Marinac CR, Martinez ME, Milne RL, Murray AM,
738 Nash D, Palmer JR, Patel AV, Pierce E, Robertson MM, Rosenberg L, Sandler DP,
739 Schurman SH, Sewalk K, Sharma SV, Sidey-Gibbons CJ, Slevin L, Smoller JW., Steves
740 CJ, Tiirikainen MI, Weiss ST, Wilkens LR, Zhang F. 2020. Risk of COVID-19 among front-
741 line health-care workers and the general community: a prospective cohort study. The
742 Lancet Public Health S246826672030164X.

- 743 48. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research
744 electronic data capture (REDCap)--a metadata-driven methodology and workflow process
745 for providing translational research informatics support. *J Biomed Inform* 42:377–381.
- 746 49. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G,
747 Delacqua F, Kirby J, Duda SN. 2019. The REDCap Consortium: Building an International
748 Community of Software Platform Partners. *J Biomed Inform* 95:103208.
- 749 50. R: The R Project for Statistical Computing. <https://www.r-project.org/>. Retrieved 18
750 October 2021.
- 751